⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKBA News
Akebia Therapeutics, Inc.
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
globenewswire.com
AKBA
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
globenewswire.com
AKBA
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
globenewswire.com
AKBA
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
globenewswire.com
AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Akebia Announces Establishment of Rare Kidney Disease Pipeline
globenewswire.com
AKBA
QTTB
Q32 Bio Sells Complement Inhibitor ADX-097
prnewswire.com
QTTB
AKBA